Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan 11;18(1):13.
doi: 10.1186/s12931-016-0498-1.

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study

Joerg Salomon  1 , Daiana Stolz  2 , Guido Domenighetti  3 , Jean-Georges Frey  4 , Alexander J Turk  5 , Andrea Azzola  6 , Thomas Sigrist  7 , Jean-William Fitting  8 , Ulrich Schmidt  9 , Thomas Geiser  10 , Corinne Wild  11 , Konstantinos Kostikas  12 , Andreas Clemens  13 , Martin Brutsche  14
Affiliations
Randomized Controlled Trial

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study

Joerg Salomon et al. Respir Res. .

Abstract

Background: Dual bronchodilator therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD). There are limited data on effects of a combination of two long-acting bronchodilators on lung function including body plethysmography.

Methods: This multicentre, randomised, double-blind, single-dose, cross-over, placebo-controlled study evaluated efficacy and safety of the free combination of indacaterol maleate (IND) and glycopyrronium bromide (GLY) versus IND alone on spirometric and body plethysmography parameters, including inspiratory capacity (IC), forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), total lung capacity (TLC) and airway resistance (Raw) in moderate-to-severe COPD patients.

Results: Seventy-eight patients with FEV1 % pred. (mean ± SD) 56 ± 13% were randomised. The combination of IND + GLY versus IND presented a numerically higher peak-IC (Δ = 0.076 L, 95% confidence interval [CI]: -0.010 - 0.161 L; p = 0.083), with a statistically significant difference in mean IC over 4 h (Δ = 0.054 L, 95%CI 0.022 - 0.086 L; p = 0.001). FEV1, FVC and Raw, but not TLC, were consistently significantly improved by IND + GLY compared to IND alone. Safety profiles of both treatments were comparable.

Conclusion: The free combination of IND + GLY improved lung function parameters as evaluated by spirometry and body plethysmography, with a similar safety profile compared to IND alone.

Trial registration: NCT01699685.

Keywords: Body plethysmography; COPD; Glycopyrronium; Indacaterol; Spirometry.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Disposition of patients
Fig. 3
Fig. 3
Improvements in a Peak Inspiratory Capacity (peak-IC) [L] (N = 74) and (b) Mean inspiratory Capacity [L] (N = 77) by IND + GLY versus IND alone
Fig. 4
Fig. 4
a Forced expiratory volume in 1 s (FEV1) [L] over time (ITT population, N = 77); b Forced vital capacity (FVC) [L] (N = 77); c Airway resistance (Raw) [cmH2O/L/s] (N = 77)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109:785–802. doi: 10.1016/j.rmed.2015.03.010. - DOI - PubMed
    1. O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:180–184. doi: 10.1513/pats.200508-093DO. - DOI - PubMed
    1. O’Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3:219–232. doi: 10.1080/15412550600977478. - DOI - PubMed
    1. Macklem PT. Therapeutic implications of the pathophysiology of COPD. Eur Respir J. 2010;35:676–680. doi: 10.1183/09031936.00120609. - DOI - PubMed
    1. Kostikas K, Siafakas NM. Does the Term “Deflators” Reflect More Accurately the Beneficial Effects of Long-acting Bronchodilators in COPD? COPD. 2016;13:537-9. - PubMed

Publication types

MeSH terms

Associated data